Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Clopidogrel for Endothelial Healing in ACS
NCT02037412Phase 4Terminated
- Sponsor
- Yonsei University
- Start
- Jan 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by Yonsei University. Primary endpoints: Stent re-endothelialization (strut coverage) at 3 months and Neointimal hyperplasia (neointimal thickness) at 3 months. Started Jan 2014; status: terminated.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02037412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037412.